U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C6H5O5S.Ca
Molecular Weight 418.41
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CALCIUM DOBESILATE

SMILES

[Ca++].OC1=CC=C(O)C(=C1)S([O-])(=O)=O.OC2=CC=C(O)C(=C2)S([O-])(=O)=O

InChI

InChIKey=QGNBTYAQAPLTMX-UHFFFAOYSA-L
InChI=1S/2C6H6O5S.Ca/c2*7-4-1-2-5(8)6(3-4)12(9,10)11;/h2*1-3,7-8H,(H,9,10,11);/q;;+2/p-2

HIDE SMILES / InChI
Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C6H5O5S
Molecular Weight 189.166
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7319004 | https://www.ncbi.nlm.nih.gov/pubmed/15312148

Calcium dobesilate (brand name Doxium) is a veno-tonic drug, which is widely prescribed in more than 60 countries from Europe, Latin America, Asia and the Middle East for three main indications: chronic venous disease, diabetic retinopathy and the symptoms of haemorrhoidal attack. This drugs also in the phase III of clinical trial is an effective adjuvant therapy, with an absence of significant side-effects, in patients with venous ulcers and stasis dermatitis. It was suggested, that the inhibitory effect of calcium dobesilate on platelet function is mediated through the cyclic AMP pathway, and probably through activation of adenyl cyclase.

CNS Activity

Originator

Esteve, A. et al.
6
Sources: Esteve A, Canal J, Laporte J. Ensayo clinico de la accion del 141-E sobre los tiempos de coagulacion y sangria. Medicina Clinica 1959; 33: 249
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16772766

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Activator
1430
Activator
1430
Activator
1430
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Doxium

Approved Use

Unknown
Primary
Approved
8429
Doxium

Approved Use

Unknown
Primary
Phase III
656
Doxium

Approved Use

Unknown
Primary
Approved
8429
DICYNONE

Approved Use

ETHAMSYLATE is a haemostatic agent. It reduces bleeding from capillaries. Oral form prescribed for the management of blood loss in menorrhagia. Parenteral form used in surgery: prevention and treatment of pre-, per-, or postsurgical capillary haemorrhages in all delicate operations and in those affecting highly vascularised tissues: E.N.T., gynaecology, obstetrics, urology, odontostomatology, ophthalmology, plastic and reconstructive surgery. It also is used in paediatrics for the prevention of periventricular haemorrhages in premature babies.
PubMed

PubMed

TitleDatePubMed
Clinical and experimental studies on the action of ethamsylate on haemostasis and on platelet functions.
1980 Sep 15
Etamsylate as inhibitor of prostaglandin biosynthesis in pregnant human myometrium in vitro.
1981 Nov 15
Effects of etamsylate on platelet functions and arachidonic acid metabolism.
1982 Dec 27
The hemostatic agent ethamsylate enhances P-selectin membrane expression in human platelets and cultured endothelial cells.
2002 Sep 15
The hemostatic agent ethamsylate promotes platelet/leukocyte aggregate formation in a model of vascular injury.
2004 Aug
Calcium dobesilate for chronic venous insufficiency: a systematic review.
2004 Mar-Apr
Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent.
2006 May-Jun
Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes.
2010 Oct
Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial.
2011 Jun
Strong Negative Interference by Calcium Dobesilate in Sarcosine Oxidase Assays for Serum Creatinine Involving the Trinder Reaction.
2015 Jun
Patents

Patents

CN102942509B
6
EP0930879A2
6

Sample Use Guides

In Vivo Use Guide
Oral. Menorrhagia - The recommended dose is 500 mg 4 times/day during menstruation. Control of hemorrhage after surgery - The recommended dose is 250-500 mg 4-6 hourly as needed. Adults. Presurgical: 1-2 ampoules i.v. or i.m. (250-500mg) 1 hour before surgery. Persurgical: 1-2 ampoules i.v. Repeat the dosage if necessary. Postsurgical: 1-2 ampoules (250-500mg) every 4-6 hours as long as the risk of bleeding persists. Emergency cases, according to the severity of the case: 1-2 ampoules i.v. or i.m. every 4-6 hours as long as the bleeding risk persists. Local treatment: soak a swab with the contents of one ampoule and apply to haemorrhagic area, or in the tooth socket after dental extraction. The application may be repeated if necessary; it may be associated with oral or parenteral administration. Children. Half the adult dose. Neonatology: 10mg per kg body weight (0,1ml=12,5mg) injected intramuscularly within 2 hours of birth then every 6 hours for 4 days.
Route of Administration: Other
In Vitro Use Guide
Under basal conditions, ethamsylate was unable to modify whole-blood platelet-leukocyte aggregation, but following whole-blood perfusion through a damaged vessel, ethamsylate produced a modest, but significant increase in platelet-leukocyte aggregates at concentrations 20-40 uM
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:44:23 GMT 2023
Edited
by admin
on Sat Dec 16 05:44:23 GMT 2023
Record UNII
5921X1560Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCIUM DOBESILATE
INN   WHO-DD  
INN  
Official Name English
CALCIUM 2,5-DIHYDROXYBENZENESULPHONATE
Systematic Name English
calcium dobesilate [INN]
Common Name English
2,5-DIHYDROXYBENZENESULFONIC ACID CALCIUM SALT (2:1)
Common Name English
DOBESILATE CALCIUM [MI]
Common Name English
CALCIUM 2,5-DIHYDROXYBENZENESULFONATE
Systematic Name English
CALCIUM DOXYBENSYLATE
Common Name English
DEXIUM
Brand Name English
BENZENESULFONIC ACID, 2,5-DIHYDROXY-, CALCIUM SALT (2:1)
Common Name English
DOXIUM
Brand Name English
205 E
Code English
HYDROQUINONE CALCIUM SULFONATE
Common Name English
205-E
Code English
Calcium dobesilate [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC C05BX51
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
WHO-ATC C05BX01
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
WHO-VATC QC05BX51
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
WHO-VATC QC05BX01
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
Code System Code Type Description
PUBCHEM
29963
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
RXCUI
1904
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY RxNorm
DRUG BANK
DBSALT002519
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
ChEMBL
CHEMBL1232131
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
CAS
20123-80-2
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
INN
2617
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
MESH
D002123
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
NCI_THESAURUS
C166829
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
ECHA (EC/EINECS)
243-531-5
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
DAILYMED
5921X1560Q
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
DRUG CENTRAL
936
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
WIKIPEDIA
Calcium dobesilate
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
SMS_ID
100000091580
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
EPA CompTox
DTXSID60173946
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
MERCK INDEX
m4709
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY Merck Index
FDA UNII
5921X1560Q
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
EVMPD
SUB06051MIG
Created by admin on Sat Dec 16 05:44:23 GMT 2023 , Edited by admin on Sat Dec 16 05:44:23 GMT 2023
PRIMARY
Related Record Type Details
Structure of DOBESILIC ACID
PARENT -> SALT/SOLVATE
Structure of CALCIUM DOBESILATE MONOHYDRATE
SOLVATE->ANHYDROUS
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966